TG Therapeutics Inc vs Twilio Inc — how do they compare? TG Therapeutics Inc trades at $54 (market cap $8.26B), while Twilio Inc trades at $195.94 (market cap $31.15B). The key difference: Twilio Inc is far larger — about 3.8× TG Therapeutics Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Twilio Inc nearer its low. Which is the better fit depends on your goals.
| TGTX | TWLO | |
|---|---|---|
Market Cap | $8.26B | $31.15B |
Sector | Health | Technology |
52-Week High | $59.06 | $236.64 |
52-Week Low | $26.39 | $92.44 |
Enterprise Value | $8.50B | $29.87B |
Trailing returns across standard periods
Latest headlines on both assets
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →Twilio Inc. is a cloud-based communication platform-as-a-service company offering communication building blocks that allow for a fully customized customer engagement experience spanning voice, video, chat, and SMS messaging. It does this through various application programming interfaces, or APIs, and prebuilt solution applications aimed at improving customer engagement. The company leverages its Super Network, a global network of carrier relationships, to facilitate high-speed, cost-effective communication.
Read more on TWLO →